Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rudolf Stadler

Showing results (81-90 of 145) with videos related to

Pageof 15
Sort By:
Leukemia|July 4, 2020
Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPNFrank Stegelmann, Kai Wille, Hannah Busen, et al.
Leukemia|November 17, 2021
Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPNFrank Stegelmann, Kai Wille, Hannah Busen, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2023
Ultrahypofractionated Low-Dose Total Skin Electron Beam in Advanced-Stage Mycosis Fungoides and Sézary SyndromeKhaled Elsayad, Carsten Weishaupt, Christos Moustakis, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 26, 2024
Practical recommendations for therapy and monitoring of mogamulizumab patients in GermanyChalid Assaf, Nina Booken, Edgar Dippel, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2018
Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task forceJulia J Scarisbrick, Emmilia Hodak, Martine Bagot, et al.
The British Journal of Dermatology|April 5, 2024
Cutaneous T-cell lymphoma care across Europe: insights from the HORIZON programmeGabriele Roccuzzo, Joana Calvão, Gabor Dobos, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 5, 2022
Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T-cell lymphomaKhaled Elsayad, Daniel Rolf, Cord Sunderkötter, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 19, 2022
Niedrig dosierte Ganzhautelektronenbestrahlung mit oraler Bexaroten-Erhaltungstherapie beim kutanen T-Zell-LymphomKhaled Elsayad, Daniel Rolf, Cord Sunderkötter, et al.
Dermatology (Basel, Switzerland)|September 2, 2021
Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma NetworkChristoph Blazejak, Rene Stranzenbach, Janika Gosman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012Reinhard Dummer, Pietro Quaglino, Jürgen C Becker, et al.
Pageof 15

Showing results (81-90 of 145) with videos related to

Sort By:
Pageof 15
Leukemia|July 4, 2020
Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPNFrank Stegelmann, Kai Wille, Hannah Busen, et al.
Leukemia|November 17, 2021
Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPNFrank Stegelmann, Kai Wille, Hannah Busen, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2023
Ultrahypofractionated Low-Dose Total Skin Electron Beam in Advanced-Stage Mycosis Fungoides and Sézary SyndromeKhaled Elsayad, Carsten Weishaupt, Christos Moustakis, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 26, 2024
Practical recommendations for therapy and monitoring of mogamulizumab patients in GermanyChalid Assaf, Nina Booken, Edgar Dippel, et al.
European Journal of Cancer (Oxford, England : 1990)|February 25, 2018
Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task forceJulia J Scarisbrick, Emmilia Hodak, Martine Bagot, et al.
The British Journal of Dermatology|April 5, 2024
Cutaneous T-cell lymphoma care across Europe: insights from the HORIZON programmeGabriele Roccuzzo, Joana Calvão, Gabor Dobos, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 5, 2022
Low-dose total skin electron beam therapy plus oral bexarotene maintenance therapy for cutaneous T-cell lymphomaKhaled Elsayad, Daniel Rolf, Cord Sunderkötter, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 19, 2022
Niedrig dosierte Ganzhautelektronenbestrahlung mit oraler Bexaroten-Erhaltungstherapie beim kutanen T-Zell-LymphomKhaled Elsayad, Daniel Rolf, Cord Sunderkötter, et al.
Dermatology (Basel, Switzerland)|September 2, 2021
Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma NetworkChristoph Blazejak, Rene Stranzenbach, Janika Gosman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 10, 2012
Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012Reinhard Dummer, Pietro Quaglino, Jürgen C Becker, et al.
Pageof 15